Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 5/20 | 0.56 |
| ▸ | ORAI1 | Q96D31 | 5/20 | 0.56 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.56 |
| ▸ | IL2 | P60568 | 9/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL766985 | 0.89 | STIM1 (0.47) | STIM1ORAI1ORAI2SCN9AGAA | |
| SCHEMBL1701956 | 0.81 | STIM1 (0.66) | STIM1ORAI1ORAI2IL2SCN9A | |
| SCHEMBL1702182 | 0.80 | STIM1 (0.77) | STIM1ORAI1ORAI2IL2 | |
| SCHEMBL10201325 | 0.80 | STIM1 (0.58) | STIM1ORAI1ORAI2IL2GAA | |
| SCHEMBL29642101 | 0.79 | STIM1 (0.65) | STIM1ORAI1ORAI2IL2GAA | |
| SCHEMBL14150380 | 0.79 | STIM1 (0.59) | STIM1ORAI1ORAI2IL2 | |
| SCHEMBL10201079 | 0.79 | STIM1 (0.65) | STIM1ORAI1ORAI2IL2GAA | |
| SCHEMBL14887381 | 0.77 | IL2 (0.56) | STIM1ORAI1ORAI2IL2SCN9A | |
| SCHEMBL18081993 | 0.76 | STIM1 (0.84) | STIM1ORAI1ORAI2IL2 | |
| SCHEMBL14881425 | 0.76 | STIM1 (0.51) | STIM1ORAI1ORAI2IL2TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619200-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012040511-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120071516-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071516-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885ORAI2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.